Nektar Therapeutics noted a potential benefit from Trump-era tariffs and onshoring policies.
1 report, 0 independent
Updated Jul 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nektar Therapeutics noted a potential benefit from Trump-era tariffs and onshoring policies.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Nektar Therapeutics
American healthcare company
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Canadian officials, including Doug Ford, are lobbying against U.S. tariffs imposed by Donald Trump due to potential negative economic impacts.
- Elastic benefits from the trend of onshoring and tariffs associated with the Trump administration.
- Trump's tariff plan caused markets to tank, impacting Donnelley Financial Solutions.
Coverage
Newest first; wire copies grouped- Unknown outlet